SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Panacos Pharmaceuticals (PANC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (38)10/26/2007 3:25:40 AM
From: idos   of 53
 
<So the 300mg cohort results look solid, good>
Agreed: There were no serious adverse events, discontinuations, or significant laboratory abnormalities. Two patients had mild adverse events, both of which were GI related, including one transient liver enzyme elevation that resolved with continued dosing (No idea if this patient was on bevirimat since the the study is blinded).
Results from phase IIa and phase IIb studies, indicates that plasma concentration and mean viral load reduction correlates. So escalating 350mg could lead to greater antiviral activity.

liquid formulation- PANC said that in order to use a solid formulation in the phase III program, only a bridging study in healthy volunteers would be required. Maybe they understood that the development of a solid formulation is essential for bevirimat’s commercial success. It will no doubt prolong its development.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News